scholarly journals Questionnaire Survey of Possible Association of Allergic Diseases with Adverse Reactions to SARS-CoV-2 Vaccination

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1421
Author(s):  
Hiroki Morimoto ◽  
Satoshi Hayano ◽  
Naoya Ozawa ◽  
Yasuaki Ogura ◽  
Hiroaki Usui ◽  
...  

To protect against COVID-19, SARS-CoV-2 vaccines have been widely used. Besides anaphylaxis, some less severe adverse effects may occur at higher frequencies. It remains unclear whether present or past histories of allergic diseases exert effects on local and systemic reactions. We conducted a questionnaire survey among workers in our hospital. We analyzed the adverse effects occurring after the first and second doses of the Pfizer–BioNTech vaccine in 955 subjects. The presence or absence of local injection reactions and systemic reactions (headache, fatigability, fever, muscle pain, and joint pain) was questioned. The intensities of these reactions were graded on a scale of 0–4 (except fever) or 0–2 (fever). The allergic diseases that we focused on were bronchial asthma, atopic dermatitis, food allergy, pollinosis, and hand eczema. For the systemic reactions, fatigability after the first dose tended to be more severe in the bronchial asthma than in the non-allergic group. Headache, joint pain, and fever tended to be more severe in the food allergy than in the non-allergic group after the second dose. For the local skin reactions, atopic dermatitis subjects tended to show rather less severe local skin reactions after the second dose. The results contribute to the guidelines for the care of individuals with different allergy histories, so that they may safely receive their vaccine.

2020 ◽  
Vol 73 (7) ◽  
pp. 1377-1383
Author(s):  
Olexandra V. Tiazhka ◽  
Zoriana V. Selska

The aim: To study the dynamics of the level of 25(ОН)D, ІL-4, ІL-10, and IgG in the blood serum of children with allergic diseases and to study the clinical effect of vitamin D3 administration n different dosage in this category of patients. Materials and methods: 153 children aged 3-16 with such allergic diseases as bronchial asthma, atopic dermatitis and allergic rhinitis have been examined. The level of 25(ОН) D was determined using the electrochemiluminescence method, while the levels of ІL-4, ІL-10 and IgG were assessed using enzyme-linked immunoassay. Results: In the contrasting of the initial level of 25(ОН)D in the blood serum of patients after administration of 2,000 IU of vitamin D3 over 2 months, after summer and after treatment with cholecalciferol in higher doses (4,000–5,000 IU) over 2 months, significant difference was established between the indicators by the Friedman criterion (λ2 = 41.211; P < 0.05). In the similar contrasting of ІL-4 indicators, a significant difference between them was traced (P < 0.05) in the period of acute disease as well as the downward tendency in the period of remission. In the similar contrasting of ІL-10 indicators, a significant difference between them was traced (P < 0.05) in the acute period and in the period of disease remission. In the similar contrasting of IgG indicators, a downward tendency was traced in the period of acute disease and significant decrease (P < 0.05) – in the period of disease remission. In the contrasting of 25(ОН)D and ІL-4, ІL-10 figures a strong reverse correlation relationship was traced. The therapeutic effect of the administration of vitamin D3 medication in different doses in children with allergic diseases was traced. Conclusions: The data obtained shows that in the treatment of children with bronchial asthma, allergic rhinitis and atopic dermatitis the complex therapy should include vitamin D3 medications in different doses within a long-term course of treatment.


Author(s):  
Vera P. Vavilova ◽  
Alexander M. Vavilov ◽  
Sofia A. Tsarkova ◽  
Irina A. Nechaeva ◽  
Ekaterina Iu. Burmistrova ◽  
...  

Background. At present, due to high prevalence of allergic diseases which start in early childhood, the search for new prevention and treatment methods is in great demand. Aim. To study the effectiveness of the Russian-produced enterosorbent colloidal silicon dioxide in the treatment of patients with food allergies combined with atopic dermatitis and gastrointestinal manifestations. Materials and methods. An open, randomized, comparative clinical study of the enterosorbent (colloidal silicon dioxide) effectiveness has been conducted in parallel groups of infants and preschool children with food allergy skin and gastrointestinal manifestations. The main groups (1 67 children with food allergies and atopic dermatitis skin manifestations, 3 60 children with food allergies and gastrointestinal manifestations) received, along with basic medication, colloidal silicon dioxide enterosorbent day at an age-specific dosage twice a for 1014 days. Control groups (2 60 children with food allergies and atopic dermatitis skin manifestations, 4 60 children with food allergies and gastrointestinal manifestations) did not receive enterosorbent. All children underwent a clinical, functional and laboratory status assessment, including medical records analysis, a pediatrician clinical examination, narrow specialists (allergist-immunologist) examination, laboratory and instrumental research. The treatment effectiveness was being evaluated on the 14th day after the initiation of therapy and after 30 days. The therapy effectiveness was assessed based on regression of skin syndrome clinical and gastrointestinal manifestations, intoxication syndrome and laboratory parameters (IgE, hemogram eosinophilia duration). The study was conducted from 2017 to 2019. On the basis of LLC Modern Medical Technologies Clinics (Kemerovo). Results. Therapy with colloidal silicon dioxide increases the significance of food allergy skin manifestations positive dynamics, which makes it possible to reduce the volume of medication and the duration of topical glucocorticosteroids use to 5.340.35 days, in the compared group 10.520.85 days (p=0.002). All patients with food allergy combined with atopic dermatitis in the main and control groups noted positive clinical dynamics, appearing as decrease in the skin inflammatory reaction area and intensity. However, the of colloidal silicon dioxide use accelerates skin syndrome condition normalization significantly (group 1 skin syndrome persisted in 2.92.0% after 14 days, in group 2 18.34.9%; p=0.003). Colloidal silicon dioxide use accelerates humoral immunity state normalization (IgE) and peripheral blood parameters (hemogram eosinophilia). Colloidal silicon dioxide therapy accelerates food allergy gastrointestinal manifestations positive dynamics in children. Two weeks after the sorbent therapy started, gastrointestinal tract lesions symptoms frequency is less than in patients in the compared group. Diarrhea frequency before treatment started was 48.36.5%, 45.06.4% in the compared groups. After two weeks it decreased to 6.73.2% with the Polisorb therapy and to 16.64.8% in the compared group (p=0.003). Abdominal pain was noted by patients of both groups equally often before the study began. After 2 weeks, abdominal pain was noted by ten percent 10.03.9% of patients taking colloidal silicon dioxide and 25.05.6% of the compared group (p=0.009). Conclusion. Taking into account the composition of the colloidal silicon dioxide, it makes sense to include this medication in childrens food allergies complex treatment starting from infancy, which contributes to a more rapid relief of gastrointestinal system damage symptoms, life quality improvement for children and their parents, and decrease in medication load. When using colloidal silicon dioxide in children with food allergies, a faster dynamics of disease symptoms relief (p=0.003) was noted, which allows us to conclude that it is highly effective in the treatment of allergic diseases associated with food sensitization.


2020 ◽  
Vol 7 (1) ◽  
pp. 5-9
Author(s):  
Dr. Mayank Surana ◽  
Dr. Vineeta Pande ◽  
Dr. Sharad Agarkhedkar ◽  
Dr. Ajit Teegala

Allergy, is a clinical expression of soluble factors like IgE, histamine or eosinophils found in serum or plasma of such patients. The products that are responsible for allergy are called as Allergens. Allergens normally induce IgE production which leads to type 1 hypersensitivity response on subsequent exposure to the same allergen. The target organs are mostly nose, lung, skin and gastrointestinal tract. Atopy is also considered as a triad of Atopic dermatitis, allergic rhinitis and bronchial asthma. Raised serum IgE and AEC are proven indicators of allergic phenomenon. Various studies show relationship between serum Immunoglobulin E level and total eosinophil count in population suffering from allergic diseases. Serum total Immunoglobulin E, total eosinophil count and specific IgE are all helpful for the diagnosis and treatment of allergic diseases. Objectives: 1.To Evaluate Serum Total IgE level in Children with allergic diseases.2. To Evaluate Absolute Eosinophil Count (AEC) in children with allergic diseases.3. To Correlate Serum Total Immunoglobulin E Level and Absolute Eosinophil Count (AEC) with allergic diseases. Methodology: Cross sectional study with 100 children in the age group 2-12 years with nasopharyngeal allergies (like bronchial asthma and atopic rhinitis) and skin allergies (like atopic dermatitis, urticaria) ,eye allergies were enrolled and serum IgE levels and AEC levels was done. Results: In present study Absolute eosinophil count was raised in 58% of cases Serum IgE was raised in 54% of cases. In present study, of 58% cases with raised Absolute eosinophil count 81% (47 cases) showed raised serum IgE levels. Conclusion: Absolute eosinophil count and serum Total IgE has been considered as a significant marker of allergic state and can be used as a marker of allergic response in atopic individuals. Raised serum IgE and AEC are more in nasobronchial allergy as compare to other systemic allergies. The elevated level of serum Total IgE and Absolute Eosinophil Count both shows Significant Correlation thus can be considered as a dependable laboratory investigation in diagnosing and categorizing allergic diseases.


Acta Naturae ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 54-64
Author(s):  
I. P. Shilovskiy ◽  
M. E. Dyneva ◽  
O. M. Kurbacheva ◽  
D. A. Kudlay ◽  
M. R. Khaitov

Cytokines of the interleukin-1 (IL-1) family play an important role in the realization of the protective functions of innate immunity and are the key mediators involved in the pathogenesis of a wide range of diseases, including various manifestations of allergy. The IL-1 family includes more than 11 members. However, the functions of many of them remain to be elucidated. Recently, new members of the IL-1 family have been discovered. In 2000, several independent research groups reported the discovery of a new interleukin of this family, which was named IL-37, or IL-1F7 (according to the new nomenclature). IL-37 was assigned to the IL-1 family based on its structural similarity with other members of this family. The study of its biological properties showed that its activity changes in inflammatory diseases, such as rheumatoid arthritis, psoriasis, as well as allergic diseases (allergic rhinitis, bronchial asthma, and atopic dermatitis). However, unlike most members of the IL-1 family, IL-37 acts as a negative regulator of inflammation. Activation of IL-37 suppresses inflammation, resulting in the suppression of inflammatory cytokines and chemokines, which in turn prevents infiltration of pro-inflammatory cells, mainly eosinophils and neutrophils. The exact molecular and cellular mechanisms of the anti-inflammatory effect of IL-37 in the development of allergic diseases (AD) have not been fully studied. This review summarizes and analyzes the accumulated experimental data on the role of IL-37 in the pathogenesis of AD, such as allergic rhinitis, bronchial asthma, and atopic dermatitis.


2020 ◽  
pp. 38-42
Author(s):  
A. I. Zariankina ◽  
M. Kh. Mirrakhimova ◽  
E. R. Shamsieva

Objective: to study the effectiveness of leukotriene receptor antagonists in the treatment foratopic pathology in children.Material and methods. 224 children with allergic diseases were prescribed to take montelucast for 3– 6 months.Results. Taking montelucast has lead to positive clinical dynamics in 75 % of the cases.A significant reduction of the eosinophil count was achieved on days 10–15 of the therapy. The Cys-LTC4/D4/E4 indices came to normal after a one-month course of montelucast therapy in 40.3 % of cases in children with bronchial asthma, in 63.3 % of cases in children with allergic rhinitis and in 60.5 % of cases in children with atopic dermatitis.Conclusions. The use of montelucast has significantly enhanced the control incidencerate ofallergic diseases in children.


PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245782
Author(s):  
Kohei Ogawa ◽  
Kyongsun Pak ◽  
Kiwako Yamamoto-Hanada ◽  
Kazue Ishitsuka ◽  
Hatoko Sasaki ◽  
...  

The association between maternal diet during pregnancy and allergy in offspring remains contentious. Here, we examined the association between maternal intake of vegetables and related nutrients during pregnancy and allergic diseases in offspring at one year of age. A cohort of 80,270 pregnant women enrolled in the Japan Environment and Children’s Study were asked to respond to a food frequency questionnaire during pregnancy and the International Study of Asthma and Allergies in Childhood questionnaire at one year postpartum. The women were categorized into quintiles according to the energy-adjusted maternal intake of vegetables and related nutrients. Using the categorizations as exposure variables, the adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were determined for the allergic outcomes, including asthma, wheeze, atopic dermatitis, eczema, and food allergy, in the offspring per quintile at one year of age. Of the 80,270 participants, 2,027 (2.5%), 15,617 (19.6%), 3,477 (4.3%), 14,929 (18.7%), 13,801 (17.2%), and 25,028 (31.3%) children experienced asthma, wheeze, atopic dermatitis, eczema, food allergy, and some form of allergic disease, respectively. The aORs of each quintile of maternal vegetable intake for all allergic outcomes were close to 1.0 compared to the lowest quintile. The lowest aOR was found in the association of maternal cruciferous vegetable intake with asthma (aOR: 0.82, 95% CI: 0.70–0.96) and highest was found in the association of maternal total vegetable intake with atopic dermatitis (aOR: 1.17, 95% CI: 1.04–1.31). The risk of allergic outcomes for the various nutrients related to vegetable consumption was close to 1.0. The maternal intake of vegetables and various related nutrients during pregnancy had little or no association with any of the allergic outcomes, including asthma, wheezing, atopic dermatitis, eczema, and food allergy, in offspring at one year.


2013 ◽  
Vol 94 (1) ◽  
pp. 55-59
Author(s):  
B A Shamov ◽  
I G Safiullina ◽  
A B Beshimova

Aim. To study the prevalence of atopic dermatitis symptoms and its relation to bronchial asthma symptoms in children of 7-8 years of age. Methods. 8880 children aged 7-8 years were examined (3000 children - in 2002, 2865 children - in 2006, 3015 children - in 2010). A questionnaire survey for atopic dermatitis symptoms was conducted as a part of international unified program «International Study of Asthma and Allergy in childhood». Results. Significant differences in prevalence of atopic dermatitis symptoms according to the questionnaire survey and as documented in medical charts were determined. The prevalence of atopic dermatitis symptoms has raised from 12.5±0.4% in 2002 to 20.4±1.5% in 2010 (р 0.001). The prevalence of atopic dermatitis symptoms early onset (younger than 2 years of age) decreased from 7.6±1.0 to 4.9±0.8% (p 0.05). The prevalence of atopic dermatitis relapses during the past calendar year increased from 3.2±0.6 to 4.8±0.8% (p 0.05). Meanwhile, the diagnosis of atopic dermatitis was set up in preadolescent children 7-8 years of age fore frequently: to 4.0±0.7% in 2002 compared to 13.8±1.3% in 2010 (p 0.001). The prevalence of atopic dermatitis and bronchial asthma combination increased from 3.4±0.4 to 7.8±1.0% (p 0.001). A strong relation between presence of atopic dermatitis symptoms and bronchial asthma symptoms was discovered (from 0.76 to 1.00, p 0.05). Conclusion. The prevalence of atopic dermatitis symptoms and bronchial asthma symptoms is still growing in preadolescent children 7-8 years of age, a relation between presence of abovementioned diseases symptoms was discovered.


2017 ◽  
Vol 14 (2) ◽  
pp. 5-9
Author(s):  
O Yu Rebrova

The previously proposed approach to the identification of priority and competitive subjects of medical research is applied to the field of science «allergology». The arguments that this area of science is the applied one are given. Search for publications on socioeconomic burden of allergic diseases in Russian Federation has been carried out, the only study on bronchial asthma has been found. Evidence gaps for medical technologies used in the allergology are identified (for atopic dermatitis as example), which represent the directions for priority research.


Sign in / Sign up

Export Citation Format

Share Document